Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
In particular, Pemetrexed with Cisplatin has demonstrated superior median overall survival, response rate, lung function and quality-of-life measures in the largest randomised trial in MPM.
His only past medical history of note was a left malignant pleural mesothelioma for which he had completed six cycles of Pemetrexed and Cisplatin chemotherapy one year previously.
The lung cancer was managed with two cycles of neoadjuvant chemotherapy (Cisplatin and Pemetrexed) followed by surgical resection.
Treatment was switched to Pemetrexed and bevacizumab.
Later, when his disease progressed on Erlotinib, we decided to give Pemetrexed with bevacizumab as subsequent therapy.